Chugai Pharmaceutical Co., Ltd. (TYO: 4519)

Market Cap	10.94T
Revenue (ttm)	1.14T
Net Income (ttm)	386.96B
Shares Out	1.65B
EPS (ttm)	235.15
PE Ratio	28.28
Forward PE	27.80
Dividend	82.00 (1.23%)
Ex-Dividend Date	Jun 27, 2024

Volume	2,700,400
Open	6,802.00
Previous Close	6,702.00
Day's Range	6,650.00 - 6,825.00
52-Week Range	4,572.00 - 7,869.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 30, 2025

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrys...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,604
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4519

Financial Performance

In 2023, Chugai Pharmaceutical's revenue was 1.11 trillion, a decrease of -11.79% compared to the previous year's 1.26 trillion. Earnings were 325.47 billion, a decrease of -13.08%.